Cart
sales@molnova.com
Chromenone 1
CAS No. 1639929-29-5
Chromenone 1( —— )
Catalog No. M35539 CAS No. 1639929-29-5
Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 255 | Get Quote |
|
| 10MG | 374 | Get Quote |
|
| 25MG | 545 | Get Quote |
|
| 50MG | 762 | Get Quote |
|
| 100MG | 1017 | Get Quote |
|
| 500MG | 2034 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameChromenone 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionChromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP).
-
DescriptionChromenone 1 is a potent osteogenic bone morphogenetic protein (BMP) potentiator. Chromenone 1 exhibits a unique mode of action as it induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs.
-
In VitroChromenone 1 rescues DMH-1-induced cardiogenesis (IC50=0.2 μM) and efficiently stimulates BMP-dependent osteogenesis from C2C12 myoblasts.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorTGF-beta/Smad
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1639929-29-5
-
Formula Weight357.29
-
Molecular FormulaC18H10F3N3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (279.88 mM; Ultrasonic )
-
SMILESO=C1C(=C(OC=2C1=CC=CC2)N3C=NC=N3)C4=CC=C(C(F)(F)F)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wesseler F, et al. Probing Embryonic Development Enables the Discovery of Unique Small-Molecule Bone Morphogenetic Protein Potentiators. J Med Chem. 2022;65(5):3978-3990. ?
molnova catalog
related products
-
L-Cycloserine
L-cycloserine irreversibly inhibit GABA pyridoxal 5′-phosphate-dependent aminitransferase in E. coli.
-
2-Deoxy-D-galactose
2-Deoxy-D-galactose is a glucose analog and glucose antagonist that inhibits the maintenance of hippocampal LTP and can suppress tumor growth by inhibiting the glycolytic process.
-
Lintuzumab
Lintuzumab (HuM-195) is a non-coupled humanized mouse monoclonal antibody directed against the cell-surface myelomonocyte differentiation antigen, CD33, with anti-leukemic activity that reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells.
